QPS Expands Clinic in Miami, Florida to Accommodate Increasing Demand for Obesity Trials
2024年5月21日 - 9:06PM
ビジネスワイヤ(英語)
QPS, a leading global contract research organization (CRO),
continues to expand and align its full-service preclinical,
bioanalysis, and clinical capabilities with the evolution of demand
for clinical trials. Today, QPS announced the expansion of its
Miami, Florida Phase I clinical trial capabilities to support the
growing needs of sponsors.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240521634782/en/
New, state of the art, clinical trial
unit at QPS Miami in South Miami, Florida USA. (Photo: Business
Wire)
QPS announces the grand opening of its newest clinical trials
unit in Miami, Florida. This new 21 bed unit will complement the
existing 85 bed clinical trials unit currently serving the Biotech
and Pharmaceutical community. With this new capacity, QPS is poised
to accommodate the rapidly increasing demand for obesity trials, as
well as continue to support complex, early phase studies in special
populations. QPS has extensive experience in allergies, asthma,
cell & gene therapy, CNS, COPD, diabetes, elderly, oncology,
pediatrics, rheumatoid arthritis, vaccines, women’s health, and
many more therapeutic areas.
“We have expanded our Phase I clinical trial capabilities to
better serve the hundreds of companies developing potential new
obesity-related drugs. We have completed more than 1,500 Phase I-IV
clinical trials for drug candidates and this expansion will enable
us to support exponentially more sponsors as they progress
compounds through proof of concept and First-in-Human trials to the
point of candidate nomination,” said Benjamin Chien, Chairman,
President, and CEO, QPS Holdings, LLC.
“Our pipeline is filled with sponsors that need this level of
support. The number of First-in-Human studies is rapidly increasing
and there are very few sites across the country that can conduct
them,” said Jose Marcos, Vice President of Clinical Operations, QPS
Miami. “QPS is well-known for its success in First-in-Human
studies. We excel at complex and special population Phase I trials,
and our enrollment and completion rates are among the best in the
industry.”
With the expansion comes an increased focus on quality. “To
ensure the quality of our clinical trials is maintained, QPS has
hired an additional full-time principal investigator to ensure
dedicated, physician-involvement at every stage of our trials,”
said Chien. “We now have five full-time principal investigators,
and a network of more than 25 board-certified subspecialty
physician investigators to support the increased volume of studies
in our pipeline.”
Wendy Marquina, MD, American Board of Obesity Medicine certified
physician, has joined QPS as a primary investigator dedicated to
Phase I trials. She brings Board Certification in Obesity, as well
as expertise in internal medicine and women’s health to QPS. Since
the discovery of the anti-obesity effects of GLP1 and GIP
inhibitors, the number of obesity-related clinical trials has
dramatically increased. More than 2,300 clinical studies related to
obesity are listed as ongoing on clinical trials.gov, and the
number is increasing as more companies join the effort to tackle
this serious disease and its related comorbidities.
“We expect this demand for obesity-related studies to continue,”
said Marquina. “Obesity trials are specialized and unique. And they
are in high demand, particularly for companies that want to find an
effective solution to this debilitating disease. The road so far is
littered with failures in this space, so there is real excitement
in the medical community that there may finally be a pathway to
help these patients.”
Supporting this expansion in Miami, QPS has co-located its
specialty lab services within its Miami-based clinical site. “In
the market, you’ll find CROs that offer clinical services, and then
you’ll find specialized labs. At QPS, we now we have the unique
combination of clinical services and a specialized lab combined
under one roof,” said Chien. “That’s important because many of our
studies require lab samples to be processed quickly, in less than
eight hours. This is only possible by having the clinical site and
specialty lab co-located.”
With this newly expanded facility and additional leadership
specializing in obesity, QPS is satisfying the need for agility,
flexibility, and speed in the global drug development community,
with a focus on serving the needs of the Biotech and Pharmaceutical
industry to support global drug development from preclinical
through post-marketing needs.
ABOUT QPS HOLDINGS, LLC
QPS is a GLP- and GCP-compliant contract research organization
(CRO) delivering the highest grade of discovery, preclinical, and
clinical drug development services. Since 1995, it has grown from a
tiny bioanalysis shop to a full-service CRO with 1,200+ employees
in the US, Europe and Asia. Today, QPS offers expanded
pharmaceutical contract R&D services with special expertise in
pharmacology, DMPK, toxicology, bioanalysis, translational
medicine, clinical trials and clinical research operations
services. An award-winning leader focused on bioanalytics and
clinical trials, QPS is known for proven quality standards,
technical expertise, a flexible approach to research, client
satisfaction, and turnkey laboratories and facilities. Through
continual enhancements in capacities and resources, QPS stands tall
in its commitment to delivering superior quality, skilled
performance and trusted service to its valued customers. For more
information, visit www.qps.com or email infopr@qps.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240521634782/en/
Gabrielle Pastore, QPS 1-302-635-4290
Gabrielle.Pastore@qps.com